Twist Bioscience (NASDAQ:TWST) CAO Robert Werner Sells 2,041 Shares

Key Points

• Robert Werner, the CAO of Twist Bioscience, sold 2,041 shares of the company's stock for approximately $65,700, reducing his holdings by 4.21%.
• Twist Bioscience's shares rose by 5.4% to $32.79 on Wednesday, with a market capitalization of $1.98 billion.
• Analyst ratings for TWST vary, with recent target price adjustments ranging from $40 to $42, while the consensus rating remains at "Moderate Buy."

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CAO Robert Werner sold 2,041 shares of the business's stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $65,699.79. Following the transaction, the chief accounting officer directly owned 46,413 shares in the company, valued at approximately $1,494,034.47. The trade was a 4.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Twist Bioscience Trading Up 5.4%

Shares of TWST stock traded up $1.67 on Wednesday, hitting $32.79. 2,438,969 shares of the stock traded hands, compared to its average volume of 1,273,207. The firm's 50-day moving average price is $27.76 and its two-hundred day moving average price is $32.84. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The stock has a market capitalization of $1.98 billion, a PE ratio of -22.61 and a beta of 2.38. Twist Bioscience Corporation has a twelve month low of $24.07 and a twelve month high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The company had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of recent analyst reports. Evercore ISI decreased their target price on shares of Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating on the stock in a research report on Tuesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a research report on Wednesday. Barclays reduced their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a research report on Thursday, October 2nd. Finally, Cowen reissued a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $48.50.

Institutional Trading of Twist Bioscience

Large investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after buying an additional 1,588,587 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Twist Bioscience by 18.5% in the 1st quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company's stock valued at $251,000 after purchasing an additional 1,006 shares during the last quarter. Strs Ohio purchased a new position in Twist Bioscience during the 1st quarter worth approximately $711,000. Wealth Enhancement Advisory Services LLC acquired a new position in Twist Bioscience during the first quarter worth approximately $396,000. Finally, GAMMA Investing LLC lifted its stake in Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after buying an additional 303 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.